Olanzapine: A 5-year perspective

Expert Review of Neurotherapeutics

Volumn 6, Issue 6, 2006, Pages 811-821

  Littrell, Kimberly H ^a   Petty, Richard G ^a   Wolf, Nicole M ^a  

^a Promedica Research Center   (United States)

Author keywords

Bipolar disorder; Clinical antipsychotic trials of intervention effectiveness study; Diabetes mellitus; Novel antipsychotics; Obesity; Schizophrenia

Indexed keywords

ALCOHOL; AMINOTRANSFERASE; CARBAMAZEPINE; CHARCOAL; CIMETIDINE; DOPAMINE RECEPTOR STIMULATING AGENT; FLUOXETINE; OLANZAPINE; OMEPRAZOLE; PERPHENAZINE; QUETIAPINE; RIFAMPICIN; RISPERIDONE; WARFARIN; ZIPRASIDONE;

AGGRESSION; BIPOLAR I DISORDER; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DELIVERY; DRUG ABSORPTION; DRUG ABUSE; DRUG BINDING; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; HEMODYNAMICS; HUMAN; HYPERGLYCEMIA; HYPERPROLACTINEMIA; IN VITRO STUDY; LABOR; NEUROLEPTIC MALIGNANT SYNDROME; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PERSONALITY DISORDER; PREGNANCY; REVIEW; SCHIZOPHRENIA; SCHIZOTYPAL PERSONALITY DISORDER; SEIZURE; STROKE; SUICIDE; TARDIVE DYSKINESIA; TRANSIENT ISCHEMIC ATTACK; VIOLENCE; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; HUMANS; SCHIZOPHRENIA;

EID: 33745512108     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.6.6.811     Document Type: Review

References (92)

1. Murray L. Physicians' Desk Reference. 6th Edition. Montvale, Thomson PDR, NY, USA (2006).
2. Markowitz JS, Devane CL, Malcolm RJ et al. Pharmacokinetics of olanzapine after single-dose oral administration of standard tablet versus normal and sublingual administration of an orally disintegrating tablet in normal volunteers. J. Clin. Pharmacol. 46(2), 164-171 (2006).
3. Tran PE, Bymaster FPE, Tye NE et al. In: Olanzapine (Zyprexa®): A Novel Antipsychotic. Lippincott Williams and Wilkins Healthcare, PA, USA (2000).
4. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin. Pharmacokinet. 37(3), 177-193 (1999).
5. Kando JC, Shepski JC, Satterlee W et al. Olanzapine: a new antipsychotic agent with efficacy in the management of schizophrenia. Ann. Pharmacother. 31(11), 1325-1334 (1997).
6. Jann MW. Clinical significance of drug binding, protein binding, and binding displacement drug interactions. Psychopharmacol. Bull. 36(3), 22-41 (2002).
7. Kassahun K, Mattiuz E, Nyhart E Jr. et al. Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab. Dispos. 25(1), 81-93 (1997).
8. Prior TI, Baker GB. Interactions between the cytochrome P450 system and the second-generation antipsychotics. J. Psychiatry Neurosci. 28(2), 99-112 (2003).
9. Carrillo JA, Herraiz AG, Ramos SI et al. Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. J. Clin. Psychopharmacol. 23(2), 119-127 (2003).
10. Shirley KL, Hon YY, Penzak SR et al. Correlation of cytochrome P450 (CYP) 1A2 activity using caffeine phenotyping and olanzapine disposition in healthy volunteers. Neuropsychopharmacology 28(5), 961-966 (2003).
11. Wright P, Birkett M, David SR et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am. J. Psychiatry 158(7), 1149-1151 (2001). • This trial against intramuscular haloperidol demonstrates the efficacy of intramuscular olanzapine.
12. Wagstaff AJ, Easton J, Scott LJ. Intramuscular olanzapine: a review of its use in the management of acute agitation. CNS Drugs 19(2), 147-164 (2005).
13. Belgamwar RB, Fenton M. Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses. Cochrane Database Syst. Rev. (2), CD003729 (2005).
14. Mattiuz E, Franklin R, Gillespie T et al. Disposition and metabolism of olanzapine in mice, dogs, and rhesus monkeys. Drug Metab. Dispos. 25(5), 573-583 (1997).
15. Caccia S. Biotransformation of postclozapine antipsychotics: pharmacological implications. Clin. Pharmacokinet. 38(5), 393-414 (2000).
16. Bymaster F, Perry KW, Nelson DL et al. Olanzapine: a basic science update. Br. J. Psychiatry 37(Suppl.), 36-40 (1999).
17. Bymaster FP, Calligaro DO, Falcone JF et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14(2), 87-96 (1996).
18. Bymaster FP, Felder CC. Role of the cholinergic muscarinic system in bipolar disorder and related mechanism of action of antipsychotic agents. Mol. Psychiatry. 7(Suppl. 1), S57-S63 (2002).
19. Bymaster FP, Hemrick-Luecke SK, Perry KW, Fuller RW. Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, α1-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology (Berl.) 124(1-2), 87-94 (1996). • This study describes the neurochemical profile of olanzapine.
20. Bymaster FP, Nelson DL, DeLapp NW et al. Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and α1-adrenergic receptors in vitro. Schizophr. Res. 37(1), 107-122 (1999)
21. 2 receptors in dopamine depleted animals. Psychopharmacology (Berl.) 142(2), 175-181 (1999).
22. Meltzer HY. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21(2 Suppl.), S106-S115 (1999).
23. Marx CE, Duncan GE, Gilmore JH, Lieberman JA, Morrow AL. Olanzapine increases allopregnanolone in the rat cerebral cortex. Biol. Psychiatry 47(11), 1000-1004 (2000).
24. Marx CE, VanDoren MJ, Duncan GE, Lieberman JA, Morrow AL. Olanzapine and clozapine increase the GABAergic neuroactive steroid allopregnanolone in rodents. Neuropsychopharmacology 28(1), 1-13 (2003).
25. Sakai K, Gao XM, Hashimoto T, Tamminga CA. Traditional and new antipsychotic drugs differentially alter neurotransmission markers in basal ganglia-thalamocortical neural pathways. Synapse 39(2), 152-160 (2001).
26. Fatemi SH, Reutiman TJ, Folsom TD et al. Chronic olanzapine treatment causes differential expression of genes in frontal cortex of rats as revealed by DNA microarray technique. Neuropsychopharmacology (2006) (Epub ahead of print).
27. Ugale RR, Hirani K, Morelli M, Chopde CT. Role of neuroactive steroid allopregnanolone in antipsychotic-like action of olanzapine in rodents. Neuropsychopharmacology 29(9), 1597-1609 (2004).
28. Freedman R. The choice of antipsychotic drugs for schizophrenia. N. Engl. J. Med. 353(12), 1286-1288 (2005).
29. Shayegan DK, Stahl SM. Atypical antipsychotics: matching receptor profile to individual patient's clinical profile. CNS Spectr. 9(10 Suppl. 11), 6-14 (2004). •• This article describes the possible future in selecting effective pharmacological agents.
30. Beasley CM Jr., Sutton VK, Taylor CC et al. Is quality of life among minimally symptomatic patients with schizophrenia better following withdrawal or continuation of antipsychotic treatment? J. Clin. Psychopharmacol. 26(1), 40-44 (2006).
31. Lambert M, Haro JM, Novick D et al. Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study. Acta. Psychiatr. Scand. 111(3), 232-243 (2005).
32. Lambert M, Holzbach R, Moritz S et al. Objective and subjective efficacy as well as tolerability of olanzapine in the acute treatment of 120 patients with schizophrenia spectrum disorders. Int. Clin. Psychopharmacol. 18(5), 251-260 (2003).
33. Moritz S, Woodward TS, Krausz M, Naber D. Relationship between neuroleptic dosage and subjective cognitive dysfunction in schizophrenic patients treated with either conventional or atypical neuroleptic medication. Int. Clin. Psychopharmacol. 17(1), 41-44 (2002).
34. Naber D, Moritz S, Lambert M et al. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr. Res. 50(1-2), 79-88 (2001).
35. Naber D, Riedel M, Klimke A et al. Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia. Acta. Psychiatr. Scand. 111(2), 106-115 (2005).
36. Wolf K, Mass R, Kiefer F et al. The influence of olanzapine versus risperidone on facial expression of emotions in schizophrenia-preliminary results of a facial electromyogram study. J. Clin. Psychopharmacol. 25(3), 278-281 (2005).
37. Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int. J. Neuropsychopharmacol. 8(3), 457-472 (2005).
38. 2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol. Psychopharmacology (Berl.) 106(4), 433-438 (1992).
39. Zimbroff DL, Kane JM, Tamminga CA et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. Am. J. Psychiatry 154(6), 782-791 (1997).
40. McGurk SR, Lee MA, Jayathilake K et al. Cognitive effects of olanzapine treatment in schizophrenia. MedGenMed. 6(2), 27 (2004).
41. Purdon SE, Jones BD, Stip E et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch. Gen. Psychiatry 57(3), 249-258 (2000).
42. Stip E, Chouinard S, Boulay LJ. On the trial of a cognitive enhancer for the treatment of schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 29(2), 219-232 (2005).
43. Jann MW. Implications for atypical antipsychotics in the treatment of schizophrenia: neurocognition effects and a neuroprotective hypothesis. Pharmacotherapy 24(12), 1759-1783 (2004).
44. Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353(12), 1209-1223 (2005). •• First report from the Clinical Antipsychotic Trial of Intervention Effectiveness study comparing atypical antipsychotics to a typical antipsychotic.
45. Hellewell JS. Patients' subjective experiences of antipsychotics: clinical relevance. CNS Drugs 16(7), 457-471, (2002).
46. Dott SG, Weiden P, Hopwood P et al. An innovative approach to clinical communication in schizophrenia: the approaches to schizophrenia communication checklists. CNS Spectrums 6(4), 333-338 (2001).
47. Collaborative Working Group on Clinical Trial Evaluations. Measuring outcome in schizophrenia: differences among the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations. J. Clin. Psychiatry 59(Suppl. 12), 3-9 (1998).
48. Cohen AS, Forbes CB, Mann MC, Blanchard JJ. Specific cognitive deficits and differential domains of social functioning impairment in schizophrenia. Schizophr. Res. 81(2-3), 227-238 (2006).
49. Keefe RS, Eesley CE, Poe MP. Defining a cognitive function decrement in schizophrenia. Biol. Psychiatry 57(6), 688-691 (2005).
50. Keefe RS, Seidman LJ, Christensen BK et al. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am. J. Psychiatry 161(6), 985-995 (2004).
51. Keefe RS, Young CA, Rock SL et al. One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophr. Res. 81(1), 1-15 (2006).
52. Kurtz MM, Moberg PJ, Ragland JD, Gur RC, Gur RE. Symptoms versus neurocognitive test performance as predictors of psychosocial status in schizophrenia: a 1- and 4-year prospective study. Schizophr. Bull. 31(1), 167-174 (2005).
53. Laes JR, Sponheim SR. Does cognition predict community function only in schizophrenia? A study of schizophrenia patients, bipolar affective disorder patients, and community control subjects. Schizophr. Res. (2006) (Epub ahead of print).
54. Baker RW, Kinon BJ, Maguire GA, Liu H, Hill AL. Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation. J. Clin. Psychopharmacol. 23(4), 342-348 (2003).
55. Hewitt J, Coffey M. Therapeutic working relationships with people with schizophrenia: literature review. J. Adv. Nurs. 52(5), 561-570 (2005).
56. Taylor M, Chaudhry I, Cross M et al. Towards consensus in the long-term management of relapse prevention in schizophrenia. Hum. Psychopharmacol. 20(3), 175-181 (2005).
57. de Haan L, van Amelsvoort T, Rosien K, Linszen D. Weight loss after switching from conventional olanzapine tablets to orally disintegrating olanzapine tablets. Psychopharmacology (Berl.) 175(3), 389-390 (2004).
58. Despres JP. Is visceral obesity the cause of the metabolic syndrome? Ann. Med. 38(1), 52-63 (2006).
59. Menza M, Vreeland B, Minsky S et al. Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program. J. Clin. Psychiatry 65(4), 471-477 (2004).
60. Evans S, Newton R, Higgins S. Nutritional intervention to prevent weight gain in patients commenced on olanzapine: a randomized controlled trial. Aust. NZJ Psychiatry 39(6), 479-486 (2005).
61. Littrell KH, Hilligoss NM, Kirshner CD et al. The effects of an educational intervention on antipsychotic-induced weight gain. J. Nurs. Scholarship 35(3), 237-241 (2003).
62. American Diabetes Association. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27(2), 596-601 (2004). •• Position paper providing guidance regarding appropriate patient monitoring.
63. Ader M, Kim SP, Catalano KJ et al. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes 54(3), 862-871 (2005).
64. Dwyer DS, Lu XH, Bradley RJ. Cytotoxicity of conventional and atypical antipsychotic drugs in relation to glucose metabolism. Brain Res. 971(1), 31-39 (2003).
65. Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, Sidhom T. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J. Clin. Psychiatry 65(4), 464-470 (2004).
66. Crow TJ, Cross AJ, Johnstone EC et al. Abnormal involuntary movements in schizophrenia: are they related to the disease process or its treatment? Are they associated with changes in dopamine receptors? J. Clin. Psychopharmacol. 2(5), 336-340 (1982).
67. Kinon BJ, Jeste DV, Kollack-Walker S et al. Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods. Prog. Neuropsychopharmacol. Biol. Psychiatry 28(6), 985-996 (2004).
68. Margolese HC, Chouinard G, Kolivakis TT et al. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: incidence and management strategies in patients with schizophrenia. Can. J. Psychiatry 50(11), 703-714 (2005).
69. Correll CU, Leucht S, Kane JM. Lower risk of tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am. J. Psychiatry 161(3), 414-425 (2004).
70. Beasley CM, Jr., Tollefson GD, Tran PV. Safety of olanzapine. J. Clin. Psychiatry 58(Suppl. 10), 13-17 (1997).
71. Clevenger CV, Furth PA, Hankinson SE, Schuler LA. The role of prolactin in mammary carcinoma. Endocr. Rev. 24(1), 1-27 (2003).
72. Koren G, Cohn T, Chitayat D et al. Use of atypical antipsychotics during pregnancy and the risk of neural tube defects in infants. Am. J. Psychiatry 159(1), 136-137 (2002).
73. McKenna K, Koren G, Tetelbaum M et al. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J. Clin. Psychiatry 66(4), 444-449 (2005).
74. Antia SX, Sholevar EH, Baron DA. Overdoses and ingestions of secondgeneration antipsychotics in children and adolescents. J. Child. Adolesc. Psychopharmacol. 15(6), 970-985 (2005).
75. Macias WL, Bergstrom RF, Cerimele BJ et al. Lack of effect of olanzapine on the pharmacokinetics of a single aminophylline dose in healthy men. Pharmacotherapy 18(6), 1237-1248 (1998).
76. Rosaria Muscatello M, Pacetti M, Cacciola M et al. Plasma concentrations of risperidone and olanzapine during coadministration with oxcarbazepine. Epilepsia 46(5), 771-774 (2005).
77. Shelton RC. The combination of olanzapine and fluoxetine in mood disorders. Expert Opin. Pharmacother. 4(7), 1175-1183 (2003).
78. Albers LJ, Ozdemir V, Marder SR et al. Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements: a prospective dose-adjusted drug interaction strategy. J. Clin. Psychopharmacol. 25(2), 170-174 (2005).
79. de Jong J, Hoogenboom B, van Troostwijk LD, de Haan L. Interaction of olanzapine with fluvoxamine. Psychopharmacology (Berl.) 155(2), 219-220 (2001).
80. Bajaj V, Comyn DJ. Norepinephrine in the treatment of olanzapine overdose. Anaesthesia 57(10), 1040-1041 (2002).
81. Bhanji NH, Chouinard G, Hoffman L, Margolese HC. Seizures, coma, and coagulopathy following olanzapine overdose. Can. J. Psychiatry 50(2), 126-127 (2005).
82. Bosch RF, Baumbach A, Bitzer M, Erley CM. Intoxication with olanzapine. Am. J. Psychiatry 157(2), 304-305 (2000).
83. Chue P, Singer P. A review of olanzapine-associated toxicity and fatality in overdose. J. Psychiatry Neurosci. 28(4), 253-261 (2003).
84. Davis LE, Becher MW, Tlomak W et al. Persistent choreoathetosis in a fatal olanzapine overdose: drug kinetics, neuroimaging, and neuropathology. Am. J. Psychiatry 162(1), 28-33 (2005).
85. Doucette DE, Grenier JP, Robertson PS. Olanzapine-induced acute pancreatitis. Ann. Pharmacother. 34(10), 1128-1131 (2000).
86. Littrell KH, Petty RG, Hilligoss NM, Peabody CD, Johnson CG. Olanzapine treatment for patients with schizophrenia and substance abuse. J. Subst. Abuse Treat. 21(4), 217-221 (2001).
87. Sayers SL, Campbell EC, Kondrich J et al. Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol. J. Nerv. Ment. Dis. 193(6), 379-386 (2005).
88. Swanson JW, Swartz MS, Elbogen EB. Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment. Schizophr. Bull. 30(1), 3-20 (2004).
89. Grootens KP, Verkes RJ. Emerging evidence for the use of atypical antipsychotics in borderline personality disorder. Pharmacopsychiatry 38(1), 20-23 (2005).
90. Keshavan M, Shad M, Soloff P, Schooler N. Efficacy and tolerability of olanzapine in the treatment of schizotypal personality disorder. Schizophr. Res. 71(1), 97-101 (2004).
91. Marazziti D, Pfanner C, Dell'Osso B et al. Augmentation strategy with olanzapine in resistant obsessive compulsive disorder: an Italian long-term open-label study. J. Psychopharmacol. 19(4), 392-394 (2005).
92. Lieberman JA, Tollefson GD, Charles C et al. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch. Gen. Psychiatry 62(4), 361-370 (2005). •• Study investigating potential neuroprotective properties of olanzapine.